Now Reading: Morepen launches first US prescription generic, shares rise 5%
-
01
Morepen launches first US prescription generic, shares rise 5%
The Story in Brief
Morepen Laboratories on Monday, 9 November, launched its first prescription generic product, Desloratadine Tablets USP, 5 mg, in the US market through its wholly owned subsidiary Morepen Bio Inc. The product is being introduced in 100-count and 500-count packs. The company said the launch extends its US presence from API supply into finished-dosage medicines.
Managing Director Sanjay Suri said the move builds on existing API relationships and reflects a strategy to build an integrated, R&D-led business. Morepen has also submitted its first ANDA to the US FDA for Sitagliptin Phosphate Tablets in 25 mg, 50 mg and 100 mg strengths, which is under review.
Shares rose as much as 5%, trading 4.8% higher at ₹98.99, ending an eight-day losing streak.
Update, 9 November 2026: The Economic Times now also reports the Desloratadine launch and the Sitagliptin ANDA submission, with copy that omits the stock reaction and the CDMO business reference that Business Standard and CNBC-TV18 included.
Indian Opinion Analysis
All three outlets led with the same newsmaker line, Morepen’s first US prescription generic launch, and carried near-identical quotes from MD Sanjay Suri, the pack sizes and the ANDA submission. Business Standard and CNBC-TV18 added the stock jump and the eight-day losing streak, The Economic Times, published earlier, omitted market reaction and the CDMO reference. No outlet framed the story as a policy win or a regulatory critique: the coverage is uniform straight reporting with minor copyediting differences. The only significant variation is what each left in or out of the first paragraph. Investors will watch the US FDA’s review of the Sitagliptin ANDA, the company’s stated next regulatory step.
Coverage: 3 sources, 3 neutral
Sources (3): business-standard.com (neutral report), cnbctv18.com (neutral report), economictimes.indiatimes.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
